ACTRN12619000870156
University, Monash University
Prof Kate Hoy
Many people with Huntington’s disease (HD) experience problems with motivation, often referred to as “apathy”. This is thought to be because of how HD affects the frontal lobes of the brain. There are currently no effective treatments for apathy in HD. Recent research has looked at whether non-invasive brain stimulation can improve motivation in people experiencing other neurological conditions (e.g., stroke) with some promising results. The type of brain changes caused by HD mean that a gentle, .... Read more
- Individuals with genetically confirmed prodromal or early stage HD, as well as individuals without HD matched for age, gender and education will be sought as participants. - Participants with prodromal HD will need to be within approximately 12 years of expected motor onset or have a “disease burden score” (DBS) of at least 280, indices calculated using the prospective participant’s current age and number of CAG repeats on the affected allele. - Participants with early stage manifest HD will n .... Read more
- Use of anticonvulsant medications or regular treatment with benzodiazepines (versus limited as-needed use, with none consumed within the 48 hours prior to an experimental session). - Commencement or significant dosage alteration of other psychotropic medications (i.e., anti-depressants, anti-psychotics) during the four weeks prior to an experimental session. - Choreiform movements that preclude tACS or EEG data collection. - A current episode of psychiatric illness, or a current substance use .... Read more
Yes
Sample Size 44
Min. age 18 Years
Max. age 75 Years
Sex Both males and females
Condition category Apathy , Huntington's disease
Condition code Human Genetics and Inherited Disorders , Neurological
Intervention code Treatment: Devices
Randomized and counterbalanced sequence of three sessions of transcranial alternating current stimulation (tACS) conducted at least 72 hours apart, with details as follows: 1) 20 minutes and 2mA at the participants peak individualised alpha frequency; 2) 20 minutes and 2mA at 2Hz (delta frequency); 3) 20 minutes of sham (placebo) with 30 seconds 'fade in' followed by an immediate 30 seconds 'fade out'. TACS is administered using a Startstim wireless hybrid electroencephalography(EEG)/transcrania .... Read more
Control group Placebo
3) 20 minutes of sham (placebo) with 30 seconds 'fade in' followed by an immediate 30 seconds 'fade out'.
Outcome: Changes in resting power on electroencephalogram (EEG).Timepoint: Resting eyes closed and eyes open EEG measured immediately before and immediately after each stimulation condition.
Outcome: Changes in event-related EEG activity during completion of the Monetary Incentive Delay (MID) task.Timepoint: The MID task completed immediately before and immediately after each stimulation condition.
yes
Individual participant de-identified data.
If and when required as part of publishing the results. Outside these circumstances, then January 2023.
Researchers who agree to preserve the confidentiality of the data, provide information regarding the proposed use of the data, and pending approval from the original research team.
As approved by the original research team.
To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.
With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.
To start requesting data, simply login with your AAF account.